Comparison · NCT04633122-sae
Ripretinib vs Sunitinib: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ripretinib vs Sunitinib: serious adverse events. Trial comparisons, record NCT04633122-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04633122-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.167 | 0.0902 | 0.287 | wilson | |
| Risk in group 2 | 0.222 | 0.132 | 0.349 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0556 | -0.204 | 0.0952 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.75 | 0.345 | 1.63 | log | |
| Odds ratio, group 1 over group 2 | 0.7 | 0.268 | 1.83 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Ripretinib than on Sunitinib | 18 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ripretinib | 50mg/tablet,150 mg QD continuous administration, 6 weeks (42 days) for a cycle.~Ripretinib: Oral kinase inhibitor | 9 | 54 | EG000 |
| Group 2 | Sunitinib | 12.5mg/capsule, 50 mg QD, in 6 weeks (42 days) with 4 weeks continuous dosing followed by 2 weeks break.~Sunitinib: second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib | 12 | 54 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Approximately 12 months.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
- NCT number
- NCT04633122
- Phases
- PHASE2
- Conditions
- Gastrointestinal Stromal Tumor(GIST)
- Interventions
- Ripretinib, Sunitinib
- Lead sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Results first posted
- 2025-01-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04633122?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04633122-sae